DERL1: A Potential Drug Target and Biomarker (G79139)

Target Name: DERL1

NCBI ID: G79139

DERL1

DERL1: A Potential Drug Target and Biomarker

The Der1-like domain family (DERL1) is a protein that has been identified in various organisms as a potential drug target and biomarker. Derl1 is a conserved protein that is found in various cellular compartments, including the endoplasmic reticulum, the cytosol, and the nucleus. Derl1 has been shown to play a role in various cellular processes, including protein transport, cellular signaling, and neurotransmission.

Recent studies have suggested that Derl1 may be a drug target due to its unique structure and its involvement in various cellular processes. One of the key reasons for this is the fact that Derl1 has a unique farnesylated cysteine residue, which is a highly reactive site that can participate in various cellular signaling pathways. This cysteine residue has been shown to play a role in the regulation of various cellular processes, including protein transport,DNA replication, and neurotransmission.

In addition to its role in cellular signaling, Derl1 has also been shown to be involved in the regulation of protein transport in the endoplasmic reticulum. This is important because the endoplasmic reticulum is the site of protein synthesis and loading, and it is the first step in the protein delivery system. Studies have shown that Derl1 plays a role in the regulation of protein transport to the endoplasmic reticulum, which may be a potential drug target in the future.

Another potential mechanism by which Derl1 may be a drug target is its role in neurotransmission. Derl1 has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for various cellular processes, including mood regulation, learning, and memory. This suggests that Derl1 may be a potential drug target for neurotransmitter-related disorders.

In conclusion, Derl1 is a protein that has been identified as a potential drug target and biomarker due to its unique structure and its involvement in various cellular processes. The conservation of the Derl1 gene in various organisms suggests that it may be a valuable target for future drug development. Further research is needed to fully understand the role of Derl1 in cellular processes and its potential as a drug target.

Protein Name: Derlin 1

Functions: Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins (PubMed:15215856, PubMed:33658201). Forms homotetramers which encircle a large channel traversing the endoplasmic reticulum (ER) membrane (PubMed:33658201). This allows the retrotranslocation of misfolded proteins from the ER into the cytosol where they are ubiquitinated and degraded by the proteasome (PubMed:33658201). The channel has a lateral gate within the membrane which provides direct access to membrane proteins with no need to reenter the ER lumen first (PubMed:33658201). May mediate the interaction between VCP and the misfolded protein (PubMed:15215856). Also involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation (PubMed:26565908). By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway (PubMed:26692333)

The "DERL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DERL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets